Imaging timing after surgery for glioblastoma: an evaluation of practice in Great Britain and Ireland (INTERVAL-GB)- a multi-centre, cohort study
INTERVAL-GB Collaborative, Tom Flannery, Harsh Bhatt, David Coope, Samantha J. Mills(University of Manchester), Ajitesh Anand, Hidayatul Abdullmalek, Melissa Gough, Emily R Bligh(University of Sheffield), Jinendra Ekanayake(Stanford University), Michael Amoo(University of Liverpool), Abbey Boyle, Ion Boiangiu, Sophie Camp(Imperial College Healthcare NHS Trust), Abdullah Egiz, Colin Watts(Cancer Research UK Clinical Trials Unit), Adam Waldman(Royal Society of Edinburgh), Neil U. Barua, Bea Duric, Justyna O. Ekert(University College London), Giles Critchley, Michael D. Jenkinson(University of Liverpool), Tomás Ferreira(University of Cambridge), Rasheed Zakaria(University of Liverpool), Gideon Adegboyega(University of Cambridge), Paul M. Brennan(Radboud University Nijmegen), Abdurrahman I. Islim(Manchester Academic Health Science Centre), Christopher P. Millward, Conor S. Gillespie(University of Cambridge), Ian Coulter, Ola Rominiyi, Chinedu Egu, Georgios Solomou, Najma Ahmed, Gerard Thompson(University of Edinburgh), Stephen J. Price(University of Cambridge), Suhaib Abualsaud, Chinelo Afulukwe, Abdelsalam Nedal Al-Sousi, Christiaan Bredell, Talhah Chaudri, Ana Cios, Anna Elso, Jeremy Cheong, Paolo Jose De Luna, Harriet Davis, Nayan Dey, Yahia Al-Tamimi, Michael TC Poon, Thomas C. Booth(King's College London)
Cited by 5
Related Papers
Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial
|The Lancet Neurology|2008|774
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
|The Lancet Oncology|2011|649
Longitudinal molecular trajectories of diffuse glioma in adults
|Nature|2019|594
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
|The Lancet|2014|436
Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice
|Nature Communications|2018|381